Janssen CarePath Savings Program

Janssen Biotech, through Janssen CarePath, offers 1 source for patient support services focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication (Table). The Janssen Compass program, designed for patients and available at JanssenCompass.com, includes patient information about each medication, educational treatment support, financial assistance information, and tools to help patients keep up with their medication regimens.

Janssen CarePath Savings Program

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to Janssen oncology medications.

Patients may qualify for enrollment in Janssen CarePath Savings programs if they have private or commercial health insurance that will cover a portion of the cost of medication. Patients participating in federal- or state-funded programs are not eligible. Drug-specific assistance information and eligibility criteria are available by selecting the appropriate drug on our website or by calling 877-227-3728, Monday-Friday, 8 am to 8 pm ET. Enrolled patients will receive a drug-specific Janssen CarePath Savings Program Card.

Balversa Janssen CarePath Savings Program

Eligible patients with private or commercial health insurance may receive savings on out-of-pocket costs for Balversa. Depending on the patient’s health insurance plan, savings may apply toward costs for copay, coinsurance, or deductible. Eligible patients pay $5 per fill, with a $25,000 maximum program benefit per calendar year. Terms expire at the end of each calendar year and may change.

Darzalex/Darzalex Faspro and Yondelis Janssen CarePath Savings Program

Eligible patients who have been prescribed Darzalex, Darzalex Faspro, or Yondelis may be able to save on their copay, deductible, and coinsurance costs for medication. Patients enrolled in the program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Yondelis or Darzalex or subcutaneous injection of Darzalex Faspro, up to a $20,000 annual benefit.

Erleada Janssen CarePath Savings Program

Eligible patients may pay only $0 per month for Erleada, with an annual benefit up to $15,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Procrit Janssen CarePath

Janssen CarePath can provide information about insurance coverage, reimbursement, affordability, and access to forms for patients who are prescribed Procrit.

Rybrevant Janssen CarePath Savings Program

Eligible patients who have been prescribed Rybrevant may be able to save on their out-of-pocket medication costs. Depending on the patient’s health insurance plan, savings may apply toward copay, coinsurance, or deductible. Eligible patients will pay $5 per infusion, with a $26,000 maximum program benefit per calendar year.

Zytiga Janssen CarePath Savings Program

Eligible patients who have been prescribed Zytiga may be able to save on their copay, coinsurance, or deductible costs. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay $10 monthly for Zytiga, up to a $12,000 annual benefit per calendar year or after 12 doses, whichever comes first.

Janssen CarePath General Resources

Access support is available online, which offers links to information on several topics, including affordability options, support for patients using government-funded healthcare programs or patients without health coverage, and the “Know Your State Interactive Tool.” It also provides a link to the Johnson & Johnson Patient Assistance Foundation, an independent, nonprofit organization that helps patients without prescription insurance coverage and without adequate financial resources to obtain their medications.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the Foundation’s patient assistance program, is available at JJPAF.org. The program is drug specific, and qualifying patients may be eligible to receive free Janssen medications for up to 12 months.

To qualify for enrollment in the Johnson & Johnson Patient Assistance Foundation, patients must:

• Lack prescription drug coverage
• Reside in the United States or its territories
• Receive outpatient treatment from a licensed US provider
• Meet drug-specific income eligibility requirements.

To apply for aid from the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form. Applications, and any required documentation, may be faxed to 888-526-5168, or mailed to the address listed on the form. The patient’s medical information, including the diagnosis (and a diagnosis code) and medication-specific information (with the dosage), must be completed. For Procrit (epoetin alfa), the hemoglobin level based on the most recent laboratory results must be included.

TABLE Janssen Biotech Oncology/Supportive Care Drugs